Specific transgene expression in HIV-infected cells using protease-cleavable transcription regulator

Daisuke Asai, Masanori Kuramoto, Yoko Shoji, Jeong Hun Kang, Kota Bae Kodama, Kenji Kawamura, Takeshi Mori, Hiroshi Miyoshi, Takuro Niidome, Hideki Nakashima, Yoshiki Katayama

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Gene therapy is a promising strategy for the treatment of HIV infection, but cell specificity remains an issue. Recently we have developed a new concept for a drug or gene delivery system responding to cellular signals (D-RECS) to achieve cell-specific transgene expression using a non-viral polymer-based vehicle. According to this concept, intracellular signaling enzymes, which are activated specifically in target cells, are used to trigger transgene expression. We previously applied this concept to HIV-1 protease and showed that the recombinant protease could act as a suitable signal. Here we further developed this system to achieve highly specific transgene expression in HIV-infected cells. We prepared a polymeric gene regulator grafted with a cationic peptide containing the HIV-Tat peptide via a specific substrate for HIV-1 protease. The regulator formed a stable polyplex with the transgene, suppressing its transcription. HIV-1 protease cleaved the peptide and released the transgene, which was consequently expressed specifically in activated HIV-infected cells, but remained unreleased and inactive in uninfected cells. The validity of this approach was further confirmed by applying it to the CVB1 2A protease of coxsackievirus (Picornaviridae family). This strategy should be widely applicable for specific expression of a variety of therapeutic genes in virus-infected cells.

Original languageEnglish
Pages (from-to)52-61
Number of pages10
JournalJournal of Controlled Release
Volume141
Issue number1
DOIs
Publication statusPublished - Jan 4 2010

Fingerprint

Transgenes
Peptide Hydrolases
HIV
Peptides
Picornaviridae
Gene Transfer Techniques
Drug Delivery Systems
Regulator Genes
Genetic Therapy
HIV Infections
Polymers
Viruses
Enzymes
Therapeutics
Genes

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Specific transgene expression in HIV-infected cells using protease-cleavable transcription regulator. / Asai, Daisuke; Kuramoto, Masanori; Shoji, Yoko; Kang, Jeong Hun; Kodama, Kota Bae; Kawamura, Kenji; Mori, Takeshi; Miyoshi, Hiroshi; Niidome, Takuro; Nakashima, Hideki; Katayama, Yoshiki.

In: Journal of Controlled Release, Vol. 141, No. 1, 04.01.2010, p. 52-61.

Research output: Contribution to journalArticle

Asai, D, Kuramoto, M, Shoji, Y, Kang, JH, Kodama, KB, Kawamura, K, Mori, T, Miyoshi, H, Niidome, T, Nakashima, H & Katayama, Y 2010, 'Specific transgene expression in HIV-infected cells using protease-cleavable transcription regulator', Journal of Controlled Release, vol. 141, no. 1, pp. 52-61. https://doi.org/10.1016/j.jconrel.2009.08.025
Asai, Daisuke ; Kuramoto, Masanori ; Shoji, Yoko ; Kang, Jeong Hun ; Kodama, Kota Bae ; Kawamura, Kenji ; Mori, Takeshi ; Miyoshi, Hiroshi ; Niidome, Takuro ; Nakashima, Hideki ; Katayama, Yoshiki. / Specific transgene expression in HIV-infected cells using protease-cleavable transcription regulator. In: Journal of Controlled Release. 2010 ; Vol. 141, No. 1. pp. 52-61.
@article{ec79b75429a84605a9b6ad79e1bd72a7,
title = "Specific transgene expression in HIV-infected cells using protease-cleavable transcription regulator",
abstract = "Gene therapy is a promising strategy for the treatment of HIV infection, but cell specificity remains an issue. Recently we have developed a new concept for a drug or gene delivery system responding to cellular signals (D-RECS) to achieve cell-specific transgene expression using a non-viral polymer-based vehicle. According to this concept, intracellular signaling enzymes, which are activated specifically in target cells, are used to trigger transgene expression. We previously applied this concept to HIV-1 protease and showed that the recombinant protease could act as a suitable signal. Here we further developed this system to achieve highly specific transgene expression in HIV-infected cells. We prepared a polymeric gene regulator grafted with a cationic peptide containing the HIV-Tat peptide via a specific substrate for HIV-1 protease. The regulator formed a stable polyplex with the transgene, suppressing its transcription. HIV-1 protease cleaved the peptide and released the transgene, which was consequently expressed specifically in activated HIV-infected cells, but remained unreleased and inactive in uninfected cells. The validity of this approach was further confirmed by applying it to the CVB1 2A protease of coxsackievirus (Picornaviridae family). This strategy should be widely applicable for specific expression of a variety of therapeutic genes in virus-infected cells.",
author = "Daisuke Asai and Masanori Kuramoto and Yoko Shoji and Kang, {Jeong Hun} and Kodama, {Kota Bae} and Kenji Kawamura and Takeshi Mori and Hiroshi Miyoshi and Takuro Niidome and Hideki Nakashima and Yoshiki Katayama",
year = "2010",
month = "1",
day = "4",
doi = "10.1016/j.jconrel.2009.08.025",
language = "English",
volume = "141",
pages = "52--61",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Specific transgene expression in HIV-infected cells using protease-cleavable transcription regulator

AU - Asai, Daisuke

AU - Kuramoto, Masanori

AU - Shoji, Yoko

AU - Kang, Jeong Hun

AU - Kodama, Kota Bae

AU - Kawamura, Kenji

AU - Mori, Takeshi

AU - Miyoshi, Hiroshi

AU - Niidome, Takuro

AU - Nakashima, Hideki

AU - Katayama, Yoshiki

PY - 2010/1/4

Y1 - 2010/1/4

N2 - Gene therapy is a promising strategy for the treatment of HIV infection, but cell specificity remains an issue. Recently we have developed a new concept for a drug or gene delivery system responding to cellular signals (D-RECS) to achieve cell-specific transgene expression using a non-viral polymer-based vehicle. According to this concept, intracellular signaling enzymes, which are activated specifically in target cells, are used to trigger transgene expression. We previously applied this concept to HIV-1 protease and showed that the recombinant protease could act as a suitable signal. Here we further developed this system to achieve highly specific transgene expression in HIV-infected cells. We prepared a polymeric gene regulator grafted with a cationic peptide containing the HIV-Tat peptide via a specific substrate for HIV-1 protease. The regulator formed a stable polyplex with the transgene, suppressing its transcription. HIV-1 protease cleaved the peptide and released the transgene, which was consequently expressed specifically in activated HIV-infected cells, but remained unreleased and inactive in uninfected cells. The validity of this approach was further confirmed by applying it to the CVB1 2A protease of coxsackievirus (Picornaviridae family). This strategy should be widely applicable for specific expression of a variety of therapeutic genes in virus-infected cells.

AB - Gene therapy is a promising strategy for the treatment of HIV infection, but cell specificity remains an issue. Recently we have developed a new concept for a drug or gene delivery system responding to cellular signals (D-RECS) to achieve cell-specific transgene expression using a non-viral polymer-based vehicle. According to this concept, intracellular signaling enzymes, which are activated specifically in target cells, are used to trigger transgene expression. We previously applied this concept to HIV-1 protease and showed that the recombinant protease could act as a suitable signal. Here we further developed this system to achieve highly specific transgene expression in HIV-infected cells. We prepared a polymeric gene regulator grafted with a cationic peptide containing the HIV-Tat peptide via a specific substrate for HIV-1 protease. The regulator formed a stable polyplex with the transgene, suppressing its transcription. HIV-1 protease cleaved the peptide and released the transgene, which was consequently expressed specifically in activated HIV-infected cells, but remained unreleased and inactive in uninfected cells. The validity of this approach was further confirmed by applying it to the CVB1 2A protease of coxsackievirus (Picornaviridae family). This strategy should be widely applicable for specific expression of a variety of therapeutic genes in virus-infected cells.

UR - http://www.scopus.com/inward/record.url?scp=70849106158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70849106158&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2009.08.025

DO - 10.1016/j.jconrel.2009.08.025

M3 - Article

C2 - 19733602

AN - SCOPUS:70849106158

VL - 141

SP - 52

EP - 61

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -